TACSTD2 and endometrial cancer: Consistent with this view, both Dato-DXd and datopotamab demonstrated significant ADCC against TROP2-positive endometrial cancer cell lines in the presence of PBMCs whereas non-targeting CTL-ADC generated only low cytotoxicity.